

Sponsor	Short title, Title	Clinical Trial Database number EudraCT/EU CT	Drug/substance and vector (if applicable)	Trial Phase	Trial Status	Disease Area	Indication	ATMP class	Cell Type	Gene Therapy	Autologous/ Allogeneic	Site(s) in Sweden	Start Year
Novartis	Cassiopeia. A phase II trial of tisagenlecleucel in first-line high-risk (HR) paediatric and young adult patients with B-cell acute lymphoblastic leukemia (B-ALL) who are minimal residual disease (MRD) positive at the end of consolidation (EOC) therapy.	NCT03876769	CTL019, Kymriah	II	In follow-up	Paediatric oncology	Paediatric and young adult patients with B-cell acute lymphoblastic leukemia (B ALL)	GTMP	T cells	Yes, ex vivo	Autologous	Karolinska University Hospital, Stockholm Sahlgrenska University Hospital, Göteborg	2021
Göteborg University	HAITILS. A Phase I Study Using Hepatic Arterial Infusion of Autologous Tumor Infiltrating Lymphocytes in Patients With Melanoma and Liver Metastases.	NCT04812470 2020-006126-31	Autologous Tumor Infiltrating Lymphocytes	I	Recruiting	Oncology - melanoma	Patients with melanoma and liver metastases		Tumor Infiltrating Lymphocytes		Autologous	Sahlgrenska University Hospital, Göteborg	2023
Merck Sharp & Dohme LLC	A Phase 3, Randomized, Double-Blind, Placebo- and Active- Comparator-Controlled Clinical study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Stage II-IV Melanoma.	NCT05933577 2023-503652-27-00	mRNA-4157 (V940). liposomally formulated mRNA.	III	In follow-up	Oncology	Malignant melanoma	GTMP	N/A	Yes, in vivo		Sahlgrenska University Hospital, Göteborg Skåne University Hospital, Lund	2023
Janssen-Cilag	CARTITUDE-5. A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants with Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy.	NCT04923893 2021-001242-35	Ciltacabtagene Autoleucel (cilta-cel) lentiviral vector	III	Recruiting	Oncology	multiple myeloma	GTMP	T cells	Yes, ex vivo	Autologous	Sahlgrenska University Hospital, Göteborg Skåne University Hospital, Lund	2022
Xintela	XIN-XSTEM-201. A single-centre, randomised, single-blind Phase I/IIa study to evaluate the safety, tolerability and efficacy of a single topical dose of allogeneic integrin $\alpha 10\beta 1$ -selected mesenchymal stem cells (XSTEM-VLU) in patients with difficult-to-heal venous leg ulcers.	NCT05549609 2022-000492-39	XSTEM-VLU	I/II	Recruiting	Skin. Chronic wounds	Venous leg ulcers	sCTMP	Integrin $\alpha 10\beta 1$ -selected mesenchymal stem cells	No	Allogeneic	Sahlgrenska University Hospital, Göteborg Skåne University Hospital, Lund	2023
European Myeloma Network	CARTITUDE-6. A Phase 3 Randomized Study Comparing Daratumumab, Bortezomib, Lenalidomide and (DVRd) followed by Ciltacabtagene Autoleucel versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in Participants with Newly Diagnosed Multiple Myeloma who are Transplant Eligible.	NCT05257083 2021-003284-10	Ciltacabtagene Autoleucel (cilta-cel) lentiviral vector	III	Recruiting	Oncology	multiple myeloma	GTMP	T cells	Yes, ex vivo	Autologous	Sahlgrenska University Hospital, Göteborg Skåne University Hospital, Lund. Uppsala University Hospital, Uppsala	2023
Sarepta therapeutics	ENVISION. A Phase 3, Multinational, Randomized, Double-Blind, Placebo-Controlled Systemic Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of SRP-9001 in Non-Ambulatory and Ambulatory Subjects With Duchenne Muscular Dystrophy.	2020-002372-13	SRP-9001/ Delandistrogene moxeparovvec	III	Recruiting	Pediatrics - Neuromuscular Duchenne muscular Dystrophy	Duchenne muscular Dystrophy	GTMP	N/A	Yes, in vivo		Sahlgrenska University Hospital, Göteborg Karolinska University Hospital, Stockholm	2022
Iovance	Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.	NCT05727904	TILs		In planning/ set-up	Oncology	malignant melanoma	sCTMP	Tumor Infiltrating Lymphocytes	No	Autologous	Sahlgrenska University Hospital, Göteborg	2024